Proton Beam Therapy

Proton beam therapy is covered for specific unresectable or anatomically challenging tumors (notably CNS tumors, intraocular melanoma, pituitary neoplasms, chordomas/chondrosarcomas, head and neck, retroperitoneal sarcoma, and pediatric solid tumors) when curative intent and dosimetric advantage are documented. Several additional site-specific indications (e.g., select lung, liver, pelvic, left breast, pancreatic, skin skull-base, and non-metastatic prostate cancer) are covered only within clinical trials or registries with required DVH/plan comparisons, staging documentation, and informed consent. Proton therapy is not indicated for widely disseminated disease, very radiosensitive tumors (lymphoma, germ cell), short-term palliative use, or when delivered with a non–FDA-approved system.

"Unresectable benign or malignant central nervous system tumors (e."

Sign up to see full coverage criteria, indications, and limitations.